Inactive Instrument

Generex Biotechnology Corporation

GNBT

US3714853013

Biotechnology & Medical Research

Generex Biotechnology Corporation Appoints Yutaka Niihara as Executive Chairman

January 25, 2017 at 01:00 pm

Emmaus announced that its Chairman and Chief Executive Officer, Yutaka Niihara, MD, MPH, has joined the Board of Directors of Generex Biotechnology Corporation as Executive Chairman.

Latest news about Generex Biotechnology Corporation

Motion for Asset Sale Approved for Generex Biotechnology Corporation	01-19	CI
Motion for Asset Sale Filed by Generex Biotechnology Corporation	12-01	CI
Motion for Asset Sale Approved for Generex Biotechnology Corporation	13/01/23	CI
Amended Bidding Procedure Approved for Generex Biotechnology Corporation	10/01/23	CI
Involuntary Petition Approved for Generex Biotechnology Corporation	06/06/22	CI
Involuntary Petition Filed Against Generex Biotechnology Corporation	23/04/22	CI
Generex Biotechnology Corporation Enters into Quality Agreement with PPD Development, L.P	23/07/21	CI
Generex Biotechnology Corporation announced that it has received $1 million in funding	14/07/21	CI
Generex Biotechnology Corporation Reports Earnings Results for the Third Quarter Ended April 30, 2021	21/06/21	CI
Generex Biotechnology Corporation Subsidiary NuGenHealth Contracts with Westside Medicine & Cardiology, Inc. to Provide Remote Patient Monitoring Services	11/05/21	CI
Generex Provides Clarification on Its Ii-Key COVID-19 Complete Vaccine China Partnership Agreement	05/05/21	CI
Generex Provides Update on Its Ii-Key COVID-19 Complete Vaccine Program: Advancing Global Development	27/04/21	CI
Generex Biotechnology Corporation Reports Earnings Results for the Second Quarter Ended January 31, 2021	17/03/21	CI
Generex Biotechnology Corporation Completes Mouse Immunogenicity Study	24/02/21	CI
Generex Biotechnology Corporation announced that it has received $1.425 million in funding	16/02/21	CI
Transcript : Generex Biotechnology Corporation - Special Call	05/02/21
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for the Complete Vaccine™	31/12/20	CI
Generex Biotechnology Corporation Reports Earnings Results for the First Quarter Ended October 31, 2020	21/12/20	CI
Nugenerex Immuno-Oncology, Inc. and Generex Biotechnology Corporation Signs an Extension for the Receipt of the USD 5,000,000.00 Upfront Licensing Fee Payment	17/12/20	CI
Generex Biotechnology Corporation and Nugenerex Immuno-Oncology Grants Licensing Rights to Bintai Healthcare Sdn Bhd	25/11/20	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand	23/11/20	CI
Generex Biotechnology Corporation Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform	18/11/20	CI
Generex Biotechnology Corporation Reports Earnings Results for the Full Year Ended July 31, 2020	13/11/20	CI
Generex Announces the Signing of A Framework Agreement with the China Cdc, Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co., Ltd on the Cooperative Development of Ii-Key Vaccines	04/11/20	CI
Generex Biotechnology Corporation appoints Tamera-Coyne Beasley to NGIO COVID-19 Vaccine Scientific & Clinical Advisory Board	30/10/20	CI

Chart Generex Biotechnology Corporation

Duration

Period

More charts

Generex Biotechnology Corporation is a life science holding company. The Company is engaged in pharmaceutical and biotechnological research and development and other activities. It is focused on building an organizational platform for the financing, development, commercialization and distribution of promising devices, biologics, therapeutic and diagnostic products to improve human health. The Company's subsidiary includes NuGenerex family of companies: NuGenerex Immuno-Oncology, Inc., NuGenerex Diagnostics, NuGenerex Health, LLC, NuGenerex Regenerative Medicine (NRM), NuGenerex Diagnostics (NGD), and NuGenerex Therapeutics. NuGenerex Immuno-Oncology, Inc. is a platform biotechnology company focused on improving the innate immune system to treat and prevent cancer and infectious disease with a pipeline of immunotherapy indications based on its patented platform technology.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+24.05%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-15.31%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs